HFA Premium Access

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.

Congress Presentation

About the speaker

Doctor Jasper Tromp

National University Health System, Singapore (Singapore)
5 presentations
2 followers

6 more presentations in this session

Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry

Speaker: Doctor D. Stolfo (Trieste, IT)

Thumbnail

Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial

Speaker: Doctor S. Chatur (Boston, US)

Thumbnail

Safety of continuing mineralocorticoid receptor antagonists treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from swedish heart failure registry

Speaker: Doctor F. Guidetti (Stockholm, SE)

Thumbnail

Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure

Speaker: Ms I. Beldhuis (Groningen, NL)

Thumbnail

Impact of lower systolic blood pressure on efficacy and safety of sacubitri/valsartan compared to ramipril in patients with acute myocardial infarction: insights from PARADISE-MI trial

Speaker: Doctor M. Senni (Bergamo, IT)

Thumbnail

Access the full session

Pharmacotherapy

Speakers: Doctor J. Tromp, Doctor D. Stolfo, Doctor S. Chatur, Doctor F. Guidetti, Ms I. Beldhuis...
Thumbnail

About the event

Image

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations